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Brain proteins are detected in the cerebrospinal fluid (CSF) and blood of stroke patients
and their concentration is related to the extent of brain damage. Antibodies against
brain antigens develop after stroke, suggesting a humoral immune response to the
brain injury. Furthermore, induced immune tolerance is beneficial in animal models of
cerebral ischemia. The presence of circulating T cells sensitized against brain antigens,
and antigen presenting cells (APCs) carrying brain antigens in draining lymphoid tissue
of stroke patients support the notion that stroke might induce antigen-specific immune
responses. After stroke, brain proteins that are normally hidden from the periphery,
inflammatory mediators, and danger signals can exit the brain through several efflux
routes. They can reach the blood after leaking out of the damaged blood-brain barrier
(BBB) or following the drainage of interstitial fluid to the dural venous sinus, or reach
the cervical lymph nodes through the nasal lymphatics following CSF drainage along
the arachnoid sheaths of nerves across the nasal submucosa. The route and mode
of access of brain antigens to lymphoid tissue could influence the type of response.
Central and peripheral tolerance prevents autoimmunity, but the actual mechanisms of
tolerance to brain antigens released into the periphery in the presence of inflammation,
danger signals, and APCs, are not fully characterized. Stroke does not systematically
trigger autoimmunity, but under certain circumstances, such as pronounced systemic
inflammation or infection, autoreactive T cells could escape the tolerance controls.
Further investigation is needed to elucidate whether antigen-specific immune events could
underlie neurological complications impairing recovery from stroke.
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INTRODUCTION
Ischemic stroke induces acute brain damage and cell death. The
lack of sufficient energy to maintain the membrane potential
of the cells causes necrosis. Necrosis, in contrast to apoptosis
or other forms of cell death, promotes a strong inflammatory
response after the intracellular content spills into the extra-
cellular environment. Stroke fuels a sterile local and systemic
inflammatory response with the release of danger signals or
damage-associated molecular patterns from the injured tissue
(Iadecola and Anrather, 2011), which could in turn stimulate
a pro-thrombotic cascade, as well as activate the innate and
adaptive arms of the immune system, with still poorly understood
consequences. Inflammation is necessary to clear the dead cells
and cell debris but it needs to be tightly regulated to avoid
excessive release of neurotoxic mediators, damage to the blood-
brain barrier (BBB), and cause uncontrolled activation of the
immune system. Cytokines, chemokines and adhesion molecules
participate in the recruitment of peripheral leukocytes that are
attracted to the injury site (Gelderblom et al., 2009). Extracellular
proteolytic enzymes are rapidly activated degrading the extracel-
lular matrix and activating pro-zymogens that cleave proteins, all
in preparation for further tissue remodeling (Yang et al., 2013).
These proteolytic processes can expose otherwise hidden epitopes
that can act as danger signals, release pro-inflammatory media-
tors, and damage the BBB. Inflammatory mediators cause indi-
rect activation of antigen-presenting cells (APCs) driving T cell
proliferation and clonal expansion, but indirectly activated APCs
cannot support differentiation of CD4+ T cells into Th1 effectors
in vivo (Spörri and Reis e Sousa, 2005). Therefore, inflammation
allows APCs to sense danger but direct danger signal recognition
is necessary to better identify the quality of the danger (Spörri and
Reis e Sousa, 2005). Danger signals activate pattern-recognition
receptors, such as toll-like receptors (TLR), inducing full matura-
tion of APCs (Janeway and Medzhitov, 1999). Although microglia
and macrophages can present antigen, dendritic cells (DCs) are
the professional APCs, and they are found in the brain after stroke
(Felger et al., 2010). Dendritic cells capture antigen mainly in its
immature stage and then undergo maturation enabling them to
efficiently present antigen by increasing the expression of MHC
II and co-stimulatory molecules, and producing cytokines that
stimulate T cells (Steinman and Nussenzweig, 2002). For efficient
naïve T cell stimulation, peripheral antigen-loaded DCs migrate
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toward tissue-draining lymph nodes. However, it is currently
unknown whether stroke-induced brain DCs migrate to the cer-
vical lymph nodes due to the absence of direct lymphatic con-
nection. Also, soluble proteins and protein fragments normally
confined to brain cells or trapped in the extracellular matrix
could reach the periphery through the leaky BBB or through
the drainage pathways of interstitial fluid and cerebrospinal fluid
(CSF; Cserr et al., 1992; Weller et al., 2009; Carare et al., 2014),
as we will describe below. Once in the periphery, brain proteins
could be taken up by APCs, processed, and presented to T cells in
lymphoid tissue.
Brain antigens were found in draining lymphoid tissue of
stroke patients (Planas et al., 2012) and mice (van Zwam et al.,
2009), suggesting that antigen-specific immune reactions could
take place after stroke. This possibility does not necessarily
imply that an immune attack to the brain would be expected
after stroke. There are indeed powerful mechanisms to control
autoimmunity ensuring tolerance (Hogquist et al., 2005), and
regulatory mechanisms operate in stroke (Liesz et al., 2009).
However, tolerance can be breached under certain circumstances
and several lines of evidence support that inflammation and/or
infection can facilitate autoimmune reactions in experimental
animal models of brain ischemia (Becker et al., 2005; Gee et al.,
2009; Zierath et al., 2010) and in human stroke (Becker et al.,
2011). While this concept is not new and some previous reviews
have addressed related issues (e.g., Becker, 2009, 2012; Vogelge-
sang and Dressel, 2011; Vogelgesang et al., 2014), we will discuss
the phenomenon of induction of tolerance in experimental stroke,
the presence of autoantibodies in stroke patients, the presence of
antigen-specific T cells in stroked animals and humans, in the
context of antigen presentation, and we will address the possible
relevance of such phenomena in medium or long-term stroke
outcome.
The effects we will be referring to in this manuscript involve
an adaptive immune response that is different from the dam-
aging effects of T cells found in the very acute phase of stroke.
Acute deleterious effects of T cells were perceived through the
protection detected in lymphocyte-deficient mice after cerebral
ischemia/reperfusion, and the capacity to reverse this phe-
nomenon by adoptive transfer of T cells (Yilmaz et al., 2006; Hurn
et al., 2007; Kleinschnitz et al., 2010). The acutely detrimental T-
cell-mediated actions are mediated, at least in part, by impair-
ment of the brain microcirculation through leukocyte adhesion
to brain vessel walls (Yilmaz et al., 2006) promoting secondary
microthrombosis (Kleinschnitz et al., 2010, 2013). Early detri-
mental effects of innate natural killer (NK) lymphocytes have
also been reported in brain ischemia (Gan et al., 2014). These
very acute lymphocyte effects contribute to the innate immune
response to stroke (Magnus et al., 2012) but are not antigen
specific and will not be addressed in this review.
BRAIN PROTEIN RELEASE TO THE PERIPHERY IN ISCHEMIC
STROKE
After cerebral ischemia, metabolites of the ischemic molecular
cascade and CNS proteins are released to the periphery, putatively
enabling the generation of autoimmune responses against brain-
specific antigens (Iadecola and Anrather, 2011; Chamorro et al.,
2012). Protein markers of cerebral damage, including myelin basic
protein (MBP), neuron-specific enolase (NSE), S100β, and glial
fibrillary acidic protein (GFAP), are found in CSF and serum after
stroke. Moreover, the concentration of these proteins is related
to the severity of the neurological deficits (Jauch et al., 2006)
and the extent of the brain lesion on neuroimaging in humans
(Jauch et al., 2006) and experimental animals (Gelderblom et al.,
2013). High levels of MBP and S100β are also predictive of poor
functional recovery (Strand et al., 1984; Missler et al., 1997;
Herrmann et al., 2000; Jauch et al., 2006). Brain antigens are
not only found in the CSF and serum but also in lymphoid
tissue of stroke patients (Planas et al., 2012; Gómez-Choco et al.,
2014) where they can be presented by APCs and could trigger
autoimmune or tolerogenic immune responses.
AUTOANTIBODIES
The presence of IgG immunoglobulin bands in the CSF of stroke
patients was reported a long time ago (Roström and Link, 1981),
suggesting that the release of brain antigens could be followed
by intrathecal B-cell responses. Other researchers have confirmed
the presence of specific IgG, IgM and IgA autoantibodies in the
CSF (Prüss et al., 2012), and this is often accompanied by pleo-
cytosis and altered albumin quotients of CSF/serum indicating
BBB dysfunction. Overall, these findings suggest local activation
of the immune system and possibly a pathogenic role of spe-
cific autoantibodies in stroke patients. Autoantibodies were also
reported in serum. For example, anti-neurofilament antibodies
were elevated after stroke, while antibodies against a ubiquitous
antigen, cardiolipin, did not increase, again suggesting that brain
antigens exposed in stroke are able to initiate an specific antibody
response (Bornstein et al., 2001). Antibodies against the NR2A/2B
subtype of N-methyl-D-aspartate (NMDA) receptor in serum
are also more frequent in patients with transient ischemic attack
(TIA) and acute ischemic stroke compared to non-stroke patients
(patients admitted with suspected stroke but who had a non-
stroke diagnosis at discharge) or healthy controls (Weissman
et al., 2011), with high sensitivity, specificity, and predictive values
(Dambinova et al., 2003). The presence of these autoantibodies
may harbinger an increased risk of stroke as identification of anti-
NMDA antibodies in patients before cardiopulmonary bypass
surgery was associated with the development of neurological
deficits and stroke (Bokesch et al., 2006). Patients with TIA and
with ischemic stroke had similar titers of antibodies to NR2A/2B,
suggesting that minor ischemic insults, and even subclinical
lesions, may be sufficient to activate immunity (Dambinova et al.,
2003). It is possible that the loss of BBB integrity is critical to allow
autoantibodies to exert pathological effects, since to some extent
the presence of autoantibodies is also seen in healthy subjects
(Hammer et al., 2013).
Antibody-producing B cells, although not numerous in
lesions, contribute to anti-atherosclerotic activity, perhaps as a
result of specific antibodies against plaque antigens, binding
of antibodies to inhibitory Fc receptors, or cytokines produced
by B cells. Spleen B cells are particularly effective inhibitors
of atherosclerosis (Caligiuri et al., 2002), possibly because cer-
tain natural antibodies produced by some of these cells recog-
nize phosphorylcholine, a molecule present in oxidized LDL,
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apoptotic cell membranes, and the cell wall of Streptococcus
pneumoniae. These antibodies may contribute to the elimina-
tion of oxidized LDL and dead cells, as well as to the defense
against pneumococcal infections. Interestingly, persons who have
undergone splenectomy have increased susceptibility not only
to pneumococcal infections but also to coronary artery diseases
(Sherer and Shoenfeld, 2006). However in experimental animals,
intrastriatal, but not systemic, administration of splenic CD19+
B-cells reduced infarct volume in B-cell deficient mice (Chen
et al., 2012) suggesting that B-cells exert protective effects against
ischemic brain injury. In human studies we found a positive
association between the number of circulating CD19+ B cells
and good functional outcome after stroke (Urra et al., 2009a).
Therefore, the role of B cell responses and antibody production in
stroke outcome is still far from being fully understood. Whether
circulating autoantibodies impair long-term functional outcome
after stroke has not been demonstrated so far but it is plausible
that they could exert pathogenic effects if they reached the brain
under particular situations where the functionality of BBB was
perturbed.
ANATOMIC PATHS THAT BRAIN PROTEINS CAN FOLLOW TO
REACH THE PERIPHERY
Brain components could reach the lymphoid tissue either through
the blood after crossing the leaky BBB, through interstitial fluid
drainage to the blood or to the cervical lymph nodes, or after
their local capture by migrating APCs (Figure 1). Understanding
the route of access of brain proteins to the lymphoid tissue is not
solely an anatomic issue, because depending on the way and form
of entry to the lymphoid tissue, brain proteins/peptides will be
encountered by different immune cells in different environments
that may strongly influence the subsequent type of response, as
we will discuss below.
Increased BBB permeability is a characteristic of stroke that
could facilitate the leakage of brain proteins or protein fragments
to the bloodstream. Proteolytic enzymes activated after stroke
damage structural BBB components and cause BBB breakdown
(Yang and Rosenberg, 2011). Neutrophils contain high levels of
metalloproteinases (MMPs), such as MMP-9, and other destruc-
tive proteolytic enzymes, normally prepared to fight microbes,
and contribute to the proteolytic activity after brain ischemia
(Justicia et al., 2003; Gidday et al., 2005). Exposure of the neu-
rovascular unit to such proteolytic activity cleaves tight junction
proteins and damages the basement membranes, eventually caus-
ing BBB breakdown in acute stroke (Cunningham et al., 2005;
Ludewig et al., 2013; Yang et al., 2013). However, BBB dysfunction
may involve different degrees of cellular, structural, and molecular
changes ranging from transient reversible dysfunction to more
long-lasting alterations. Results obtained with different methods
assessing BBB permeability support that there must be different
grades of BBB dysfunction after brain ischemia (Nagaraja et al.,
2008). The extent and nature of such alterations might exert some
selectivity in the actual leakage of CNS protein components to the
circulation, based on their size and other physical or biochemical
features.
Besides exiting the brain through the leaky BBB, brain
molecules can reach the periphery through the anatomic paths
that allow for direct interstitial fluid drainage by bulk flow to
the blood or to the lymphatics (Cserr et al., 1992; Weller et al.,
1992; Abbott, 2004). The physical connection circuitry out of the
brain towards the immune system enables draining of CSF into
the lymphatics (Cserr et al., 1992; Weller et al., 1992). Interstitial
extracellular fluid from the brain tissue drains to the CSF through
perivascular spaces surrounding brain arterioles, but not venules
(Arbel-Ornath et al., 2013; Carare et al., 2014). Perivascular
spaces are connected to the subarachnoid space, allowing for
fluid drainage to the venous blood through the arachnoid villi
located at the dural venous sinuses (Cserr et al., 1992; Ransohoff
et al., 2003). In addition, fluid from the subarachnoid space
drains directionally to the cervical lymph nodes (Cserr et al.,
1992; Zhang et al., 1992; Carare et al., 2014). Olfactory nerves are
ensheated by arachnoid membranes allowing the drainage of CSF
to the nasal mucosa through the cribiform plate, reaching nasal
lymphatics, and from there, the CSF drains to the cervical lymph
nodes (Harling-Berg et al., 1989; Cserr et al., 1992). An example of
the functional relevance of this pathway is that the cervical lymph
nodes are involved in the systemic humoral immune response to
antigen infused into rat cerebrospinal fluid (Harling-Berg et al.,
1989). Impairment of drainage of interstitial fluid out of the
brain is believed to play a crucial role in the failure to adequately
eliminate amyloid-β from the brain promoting its accumulation
in the arterial walls in the elderly, and more prominently in
patients with cerebral amyloid angiopathy (Weller et al., 2008;
Hawkes et al., 2011, 2014; Arbel-Ornath et al., 2013). Since the
force driving perivascular drainage is attributed to arterial vessel
pulsations, it is not surprising that fluid drainage was found to
be obstructed in an experimental model of focal brain ischemia
induced by photothrombosis (Arbel-Ornath et al., 2013). This
finding implies that stroke could impair the possible transfer of
brain antigens from the interstitial fluid of the ischemic tissue to
the CSF, but might not necessarily prevent the transfer connection
from CSF to the cervical lymph nodes. In any case, ischemia-
induced bulk-flow alterations might reverse, at least in part, at
reperfusion.
Besides the possible exit of brain antigen from the brain
tissue in a soluble form through the pathways indicated above
(Figure 1), antigen can also be taken up locally in the brain
by APCs. Dendritic cells (CD11c+) expressing MHC II and co-
stimulatory molecules are found in the ischemic tissue (Felger
et al., 2010) suggesting that they can present antigen. Migrat-
ing DCs traffic from peripheral tissues to their nearest lymph
nodes through a process orchestrated by CCR7 in response
to chemokines CCL19 and CCL20 (Förster et al., 1999), but
other pathways could also be implicated such as sphingosine-
1-phosphate (S1P) signaling (Czeloth et al., 2005) or the MHC
II invariant chain (CD74) (Faure-André et al., 2008). Since the
brain lacks lymphatic vessels, it is currently unknown whether
mature DCs carrying antigen can migrate from the injured brain
tissue to the peripheral lymphoid tissue. It was reported that
cells from the brain could reach the deep cervical lymph nodes
through the nasal submucosa (Cserr et al., 1992), supporting
that cells in the subarachnoid space might be able to reach
the draining lymph nodes. This possibility would imply that
APCs could follow chemoattractant gradients along the anatomic
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FIGURE 1 | Routes for the presentation of brain antigens in the lymphoid
tissue. Brain antigens can reach regional lymphoid tissue through various
routes after stroke. Ischemic stroke increases BBB permeability that can
allow the leakage of proteins or peptides into the blood. Soluble
proteins/peptides in brain interstitial fluid can reach the CSF through
perivascular spaces and flow to the venous blood through the arachnoid villi
or drain from the CSF may also drain along the arachnoid sheaths of the
olfactory nerves towards the regional lymphatics. Although brain antigens are
depicted as traveling in a soluble form in the figure, it is also possible that
peptides were internalized, processed and presented by APCs in the brain,
and that they reached regional lymph nodes through migrating APCs. Antigen
presentation in the lymph nodes will usually induce tolerance to self-antigens,
but under some circumstances that favor an inflammatory milieu presentation
of brain antigens may result in activation of autorreactive T cells.
connections between the CSF and the cervical lymph nodes
playing a natural role in the process of brain immunosurveillance.
A study injecting DCs into the brain parenchyma showed little
migration from their site of injection and cells did not reach
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the cervical lymph nodes, while intra-CSF-injected DCs did, and
they preferentially targeted B-cell follicles rather than T-cell-rich
areas suggesting that they favored humoral responses rather than
cellular immunity (Hatterer et al., 2006). Efflux of solutes injected
into the interstitial fluid of the brain was found to take place
along basement membranes in the walls of capillaries and arteries
(Carare et al., 2008). These basement membranes are very narrow,
about 100 nm-thick, and therefore in normal conditions this
pathway does not seem to be large enough to allow the trafficking
of cells (Carare et al., 2008, 2014). Therefore, further studies are
needed to find out whether and how mature APCs exit the brain
to reach the peripheral lymphoid tissue after stroke.
ANTIGEN PRESENTATION: IMMUNITY VS. TOLERANCE
We identified in human stroke an increased presence of brain-
derived antigens in migrating DCs and macrophages in lymphoid
tissue located within the draining pathways of the CNS (Planas
et al., 2012). This finding extends previous observations accrued
in the cervical lymph nodes of rodents with ischemic brain
damage or autoimmune disease, and in patients with multiple
sclerosis (de Vos et al., 2002). These studies raise the issue of
whether APCs in lymph nodes can present brain antigens to
T cells after acute brain damage, and whether they can induce
immune reactions that will either exacerbate the brain injury
or promote mechanisms of T-cell tolerance. Central tolerance
ensures, through negative selection, the elimination of most T
cells recognizing self-antigens in the thymus. This process is com-
plemented with peripheral tolerance that guarantees tolerization
of autoreactive T cells and involves the action of peripheral APCs
(Steinman and Nussenzweig, 2002). Cytoplasmic endogenous
peptides are processed mostly through the proteasome, loaded
into MHC class I in the endoplasmic reticulum, and shuttled to
the cell membrane through the secretory pathway for presentation
by MHC I in all cells, allowing recognition by CD8+ cytotoxic
lymphocytes (Hulpke and Tampé, 2013). In contrast, exogenous
peptides are presented through MHC class II after capture by
APCs through endocytosis, including pinocytosis, phagocyto-
sis, and receptor-mediated endocytosis (Wilson and Villadangos,
2005). Antigen presentation through MHC II elicits responses in
CD4+ T helper (Th) cells. The exception to this role is cross-
presentation of exogenous antigens by APCs through MHC I.
This process occurs when exogenous peptides from the cell envi-
ronment reach the cytoplasm, are presented through MHC I, and
activate CD8+ T cells (Heath and Carbone, 2001; Joffre et al.,
2012).
Presentation of exogenous proteins by APCs through MHC II,
and also through cross-presentation, is essential for T cell priming
against invading pathogens and for the induction of tolerance to
self-tissue-specific proteins. Immune tolerance to self-antigens is
based on the regulation of autoreactive lymphocytes by several
mechanisms including deletion, clonal anergy, or suppression by
regulatory T cells (Tregs) and other regulatory cells (Goodnow
et al., 2005), and is dependent on the features of the interactions
between T cells and APCs (Heath and Carbone, 2001). Dendritic
cells are tolerogenic according to their maturation and functional
status and are able to delete or silence autoreactive T cells and
facilitate the development of Tregs (Rescigno, 2010; Ganguly
et al., 2013), which play critical roles in controlling autoimmunity
(Sakaguchi et al., 2001). Endogenous Tregs increase after exper-
imental brain ischemia (Offner et al., 2006), and they pro-
liferate and accumulate in the ischemic tissue up to 30 days
after middle cerebral artery occlusion (MCAO; Stubbe et al.,
2013). Regulatory T cells are involved in suppressing potentially
harmful immune responses in stroke through the production of
interleukin 10 (IL-10; Liesz et al., 2009), although some studies
found no differences in the neurological outcome of stroke after
depleting CD25(+) Tregs (Stubbe et al., 2013). Enhancing the
immunosuppressive function of Tregs with histone deacetylase
inhibitors was reported to reduce ischemic brain damage (Liesz
et al., 2013). Immunotherapies with Tregs are currently under
investigation to promote immune tolerance in various diseases
(Singer et al., 2014). However, the effects of exogenous Treg
administration in experimental brain ischemia are controversial,
with some studies reporting protective actions (Li et al., 2013a,b),
and other studies finding damaging effects related to the non-
antigen specific impairment of the microcirculation (Kleinschnitz
et al., 2013), as attributed to other T cells (Kleinschnitz et al.,
2010). Regulatory B cells (Bregs) also produce IL-10 and TGF-
β and exert immunomodulatory functions contributing to the
maintenance of self-tolerance (Vadasz et al., 2013). Interleukin 10
producing Bregs were found to exert protection in experimental
brain ischemia in mice, and Breg administration increased Treg
numbers and the expression of the co-inhibitory receptor pro-
grammed death (PD)-1 (CD279) (Ren et al., 2011a; Bodhankar
et al., 2013a).
The pathway of antigen access to the draining lymphoid tissue
might influence the type of immune response since immature
DCs that are resident in the lymph nodes efficiently take up,
process and present antigen to induce tolerance (Inaba et al.,
1997). Soluble brain peptides traveling through afferent lym-
phatic vessels to lymph nodes could be taken up by APCs or
could be degraded extracellularly since immature DCs secrete
proteases able to generate antigens that are eventually loaded on
surface MHC II molecules (Santambrogio et al., 1999). Therefore,
brain proteins or peptides reaching the lymphoid tissue in a
soluble form could be internalized by resident macrophages or
by immature DCs following prior extracellular degradation. We
did not detect brain-derived antigens in lymphoid tissue resi-
dent DCs after stroke, but the brain-antigen loaded APCs were
compatible with macrophages and migratory DCs (Planas et al.,
2012). Antigen presentation by macrophages or DCs seems to
be dependent on the form of antigen delivery to the cells, pos-
sibly due to different cell-type dependent internalization mecha-
nisms. Dendritic cells preferentially internalize protein fragments
whereas native proteins are better taken up by macrophages after
receptor-mediated internalization or phagocytosis of apoptotic
cells (Tsark et al., 2002). Dendritic cells are more efficient APCs
than macrophages since they process antigen through a mecha-
nism better preserving epitopes for T cell activation (Savina et al.,
2006), whereas macrophages induce a very strong lysosomal acid-
ification for protein degradation and display a different repertoire
of lysosome proteases than DCs (Burster et al., 2005). Interest-
ingly, we observed contacts between brain-antigen immunoreac-
tive APCs and lymphoid resident DCs (Planas et al., 2012), which
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suggested the possibility of cargo exchange between these cells. It
has been reported that antigens can be transferred from migrating
APCs to lymph node-resident DCs for presentation and priming
of cytotoxic lymphocytes (Allan et al., 2006). Cell-to-cell antigen
transfer can be mediated through gap junctions (Neijssen et al.,
2005). A recent study showed connexin 43 gap junction-mediated
transfer of antigen from macrophages to CD103+ DCs, and the
involvement of this process in the establishment of oral toler-
ance (Mazzini et al., 2014). Another pathway of possible antigen
transfer between cells is via exosomes, i.e., externalized endosomal
vesicles secreted by different cell types including DC and B cells.
Exosomes are formed by direct fusion of membranes of the MHC
II-enriched compartment with plasma membrane containing co-
stimulatory molecules such as CD86 (Raposo et al., 1996; Denzer
et al., 2000; Harvey et al., 2007). These vesicles are transferred
from cell-to-cell by adherence to the cell surface rather than by
membrane fusion (Denzer et al., 2000). The expected response to
antigen transfer mediated by gap junctions or by exosomes would
be different since the latter carry co-stimulatory molecules. It is
unknown whether any of these mechanisms could support the
transfer of brain antigen from macrophages or migrating DCs to
resident DCs in the lymph node after stroke, and whether such
processes could be involved in tolerization.
The maintenance of peripheral tolerance involves cross-
presentation (Belz et al., 2002). CD8+ T cells recognizing self-
antigen with high affinity are eliminated in the peripheral lymph
nodes, and this process is termed cross-tolerance (Redmond and
Sherman, 2005). Myelin-specific CD8+-T-cells play a pathogenic
role in experimental models of multiple sclerosis (Huseby et al.,
2001). Cross-presentation requires that the internalized Ag in
the endosomal compartment access the cytosol. This process is
regulated in diverse ways by chaperone proteins of the heat-shock
family (HSPs) that prevent protein aggregation and misfolding
(Srivastava, 2002). Heat-shock proteins mediate the transfer
of antigenic peptides from the endosome compartment to
the cytosol facilitating cross-presentation in immature DCs
(Todryk et al., 1999), which then interact with cytotoxic T cells
in an antigen-dependent fashion (Noessner et al., 2002; Binder
and Srivastava, 2005). Also, HSPs undergo receptor-mediated
endocytosis in DCs (Arnold-Schild et al., 1999), and induce
maturation and migration of DCs (Binder et al., 2000). HSP-70
is not normally expressed in the brain under physiological
conditions but is highly induced after ischemia (Planas et al.,
1997; de la Rosa et al., 2013). HSP-70 is released from necrotic
cells to the extracellular space (Todryk et al., 1999), and it can
reach the bloodstream (Campisi and Fleshner, 2003). Because
of the immunological properties of HSPs, the high induction of
HSP-70 in the ischemic brain, and the presence of HSP-70 in
the blood, led us to deduce that APCs in peripheral lymphoid
tissue might carry HSP-70 after stroke. Indeed, we found that
stroke patients showed higher immunoreactivity to HSP-70 and
more HSP-70 immunoreactive APCs in lymphoid tissue than the
controls, and that stronger presence of HSP-70 in lymphoid tissue
was associated with smaller infarctions and better functional
outcome (Gómez-Choco et al., 2014). Although a causal
relationship between the presence of HSP-70 in the lymphoid
tissue and the better outcome of the patients was not proved, it
is feasible that the immunoregulatory properties of HSP-70 could
modulate autoimmune responses after stroke. In other situations,
HSP-70 has been implicated in the development of autoimmunity
by promoting inflammatory responses, enhancing DC antigen
presentation, and cytotoxic lymphocyte function (Millar et al.,
2003) and it is involved in direct chaperoning of antigens into DCs
(Todryk et al., 1999). While other HSP proteins, such as HSP-90,
facilitate cross-presentation by antigen transfer to the cytosol
(Imai et al., 2011), recent data support that HSP-70 impairs it
(Kato et al., 2012), thus implying that HSP-70 might favor MHC
II presentation. Although exposure of DCs to HSP-70 attenuates
T cell responses (Stocki et al., 2012) and HSP-70 improves the
immunosuppressive functions of Tregs, it also activates effector
T cells (Wachstein et al., 2012). However, brain-derived HSP-70
has been involved in the induction of regulatory NK cells that can
induce tolerance in experimental autoimmune encephalomyelitis
(Galazka et al., 2006, 2007). Therefore, HSP-70 exerts diverse
and complex actions in the immune system and further study is
required to understand its role in stroke immunity.
ANTIGEN-SPECIFIC T CELLS
Whether the immune response to acute brain injury is non-
specific or is directed against specific brain antigens is not yet
settled. While tolerogenic effects have been reported with vac-
cination using neural antigens, several lines of evidence suggest
that T cell accumulation at the site of traumatic CNS injury
lacks selectivity, as shown after systemic administration of pas-
sively transferred T cells recognizing either neural self-antigen
or non-self-antigen, since it resulted in accumulation of the T
cells in injured optic nerve regardless of the antigen used for
immunization (Hirschberg et al., 1998). The latter effects could
be more related to non-specific effects of T cells described at
early reperfusion following brain ischemia (Kleinschnitz et al.,
2010). Nonetheless, evidences for antigen-specific T-cell reactivity
have been found in animal models of acute brain injury. Indeed,
nerve trauma can trigger the expansion of myelin-reactive T
lymphocytes (Olsson et al., 1992) and an abnormal abundance
of T cells autoreactive to myelin was reported in peripheral
nerve trauma (Olsson et al., 1992), or spinal cord injury (Kil
et al., 1999). While in the spinal cord endogenous MBP-reactive
lymphocytes activated by traumatic injury can contribute to
tissue damage and impair functional recovery (Jones et al., 2002),
several lines of evidence support beneficial effects of these cells
in the CNS (Graber and Dhib-Jalbut, 2009). Modulation of
immune responses by priming T-cells with neural antigens has
shown beneficial neuroprotective and anti-inflammatory actions
in models of acute brain injury. Notably, autoreactive type-1
and -2 memory T cells pre-primed with myelin oligodendro-
cyte glycoprotein (MOG), a protein expressed on the surface of
oligodendrocytes and myelin sheaths that is exclusive of nervous
system, accelerated re-vascularization and healing following post-
traumatic brain injury (Hofstetter et al., 2003). Furthermore,
passive transfer of MBP-autoimmune T cells protected injured
neurons in the CNS from degeneration (Moalem et al., 1999), and
a possible contribution of a neurotrophin-related mechanism was
proposed (Barouch and Schwartz, 2002). In experimental stroke,
systemic inflammation at the time of MCAO in rats induced the
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development of a deleterious autoimmune response to MBP after
1 month (Becker et al., 2005). Furthermore, in a similar exper-
imental model, impairment of neurological deficits associated
with a Th1 response to MBP in the spleen was reported as soon
as 48 h after induction of ischemia (Zierath et al., 2010). Further
studies are needed to clarify the time-course development of
antigen-specific reactions after stroke and their possible negative
impact in functional outcome.
In stroke patients, antigen-specific T-cell reactivity (Tarkowski
et al., 1991a,b) and in vivo expansion of myelin reactive T
cells in the CSF (Wang et al., 1992) were observed more than
20 years ago. Increased influx of MOG-specific T cells into
the brain was also detected after experimental stroke (Dirnagl
et al., 2007). Th1 responses against MBP ranged from 24% in
patients with no stroke-associated infection to 60% in patients
with pneumonia and more robust Th1 responses to MBP 90
days after human stroke were associated with a decreased like-
lihood of good functional outcome, even after adjusting for
major independent prognostic factors such as baseline stroke
severity and age. Responses to another myelin-associated anti-
gen, myelin proteolipid protein (PLP), and to the astrocyte
marker GFAP also seemed to be associated to poor outcome,
but reactivity to other antigens such as NSE, S-100β, and tetanus
toxin were not predictive of outcome (Becker et al., 2011). The
diverse prognostic consequences of immune responses to dif-
ferent brain antigens were also seen when analyzing the pres-
ence of brain-derived antigens in the lymphoid tissue of stroke
patients. Greater reactivity to MBP was correlated with stroke
severity on admission, larger infarctions, and worse outcome
at follow-up, whereas increased reactivity to neuronal-derived
antigens, such as microtubule-associated protein-2 and NMDA
receptor subunit NR-2A, was correlated with smaller infarctions
and better long-term outcome (Planas et al., 2012). Interestingly,
in cervical lymph nodes of multiple sclerosis patients, neuronal
antigens were present in pro-inflammatory APCs, whereas the
majority of myelin-containing cells were anti-inflammatory (van
Zwam et al., 2009). The authors concluded that the presence
of myelin and neuronal antigens in functionally distinct APC
populations suggests that differential immune responses can be
evoked.
It is not settled whether autoimmune responses are the cause
or a consequence of severe ischemic damage but the opposing
prognostic implications of immune responses to specific brain
antigens do suggest a pathogenic role of autoimmune responses
against myelin antigens. Fast-conducting myelinated tracts are
responsible for long-range connectivity, interhemispheric syn-
chronization, and also have neurotrophic effects (Dan and Poo,
2004; Nave, 2010) and injury to these fibers can therefore impair
brain connectivity (Sun et al., 2011; Lawrence et al., 2013), reduce
cortical blood flow, and promote cerebral atrophy (Appelman
et al., 2008; Chen et al., 2013). Given that myelination is impor-
tant for neuroplasticity and motor learning (Fields, 2010), greater
autoimmune damage to myelin could also compromise recov-
ery after stroke and contribute to cognitive impairment. It is
unknown whether antigen-specific responses to molecules widely
expressed in the body might also develop after stroke. Patients
with antiphospholipid syndrome are at risk of stroke (Sciascia
et al., 2014) and this may have additional implications regard-
ing whether existing autoantibodies can impair the functional
outcome of stroke, or whether stroke could exacerbate pre-
existing autoimmune responses.
INDUCTION OF IMMUNOLOGIC TOLERANCE IN STROKE
Seminal studies by the team of J. Hallenbeck, K. Becker and col-
leagues provided evidences supporting that modulating antigen-
specific responses could protect the brain in stroke. They found
that oral administration of low doses of bovine MBP to Lewis
rats prior to transient (3-h) MCAO reduced infarct volume
at days 1 and 4 (Becker et al., 1997) demonstrating induced
antigen-specific modulation of the immune response. This strat-
egy reduced delayed-type hypersensitivity to MBP and induced-
spleen cell proliferation showing that tolerance to this brain
antigen was induced. Similar findings were reproduced using
MBP for tolerization through nasal instillation in Lewis rats,
which showed reduced infarct volume 24 h after 3-h intraluminal
MCAO (Becker et al., 2003). Notably, the latter study showed
that the protective effect of MBP tolerization could be transferred
by administration of splenocytes from MBP-tolerized donors
before induction of MCAO, implying that the protective effect
of tolerization can be conferred by splenocyte transplantation.
In the same line, nasal vaccination with a MOG peptide prior to
transient (2-h) MCAO in C57BL/6 mice reduced infarct volume
and was more effective than oral MOG tolerization (Frenkel
et al., 2003). Besides tolerization with brain-specific antigens,
repetitive nasal administration of small doses of E-selectin was
also beneficial in experimental stroke. E-selectin is an adhesion
molecule involved in leukocyte trafficking to the tissues across the
blood vessels and it is strongly induced in the inflamed endothe-
lium. E-selectin expression in the brain vasculature increases after
cerebral ischemia (Huang et al., 2000). In prevention studies, nasal
instillation of E-selectin potently inhibited the development of
ischemic and hemorrhagic strokes in stroke-prone spontaneously
hypertensive rats (SP-SHR; Takeda et al., 2002). Moreover, induc-
tion of mucosal tolerance to E-selectin through nasal instillation
before induction of permanent MCAO (coagulation) in SP-SHR
rats improved the outcome by reducing infarct volume at 48 h
(Chen et al., 2003). This study also found that adoptive transfer of
splenocytes from E-selectin-tolerized donors was able to reduce
infarct volume.
But what is the actual mechanism underlying the protection
conferred by antigen-specific tolerization against stroke brain
damage? Interleukin-10-producing CD4+ T cells mediated
the protective effect of nasal tolerization with MOG (Frenkel
et al., 2003, 2005), in agreement with the concept that mucosal
administration of proteins preferentially induces IL-10 responses
mediated by tolerogenic DCs and Tregs (Weiner et al., 2011).
Likewise, oral administration of MOG protected against sec-
ondary neurodegeneration in a rat model of acute nerve injury by
induction of IL-10 producing myelin-reactive T cells (Monsonego
et al., 2003). However, nasal MOG tolerization in stroke induced
more IL-10 and less CD11b cells than oral MOG (Frenkel et al.,
2003). Interleukin-10 production induces unresponsiveness in
innate myeloid cells, which then become less capable of generating
IL-17-producing encephalitogenic T cells. Oral MBP tolerization
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induced TGF-β1 and the immunosuppressive features of this
cytokine might underlie the beneficial effects of MBP tolerization
in stroke (Becker et al., 1997). Mucosal E-selectin tolerization
downregulated MHC class I gene expression (Illoh et al., 2006).
This effect could prevent the activation of NK cells or cytotoxic
T cells and was associated with reduced numbers of CD8+ cells
found after ischemia in the tolerized animals (Chen et al., 2003).
Tolerization with E-selectin reprogrammed gene expression to
inflammation induced by lipopolysaccharide (LPS) promoting
the expression of growth factor genes and genes involved in
protection against oxidative stress, and it was suggested that
E-selectin tolerization could lead to the expansion of Tregs
(Illoh et al., 2006). Again, increased expression of IL-10 was also
proposed as a mechanism underlying the protective effects of
E-selectin tolerization (Yun et al., 2008). Induction of mucosal
tolerance triggers Tregs in an antigen-specific fashion (Weiner
et al., 2011). Regulatory T cells attenuate inflammation and
prevent autoimmunity through secretion of immunosuppressive
cytokines, amongst other effects (Costantino et al., 2008). Then,
Tregs can exert a global non-specific suppressive effect locally
where they encounter the specific antigen, and this action
could mediate, at least in part, the beneficial effects of mucosal
tolerization in stroke (Frenkel et al., 2005).
THE EFFECT OF SYSTEMIC INFLAMMATION
Large community studies have found associations between sys-
temic inflammatory conditions, such as osteorarthritis or pelvic
inflammatory disease, and cardiovascular disease, including
stroke (Chen et al., 2011; Rahman et al., 2013). This could be
the result of the profound implication of many components of
the immune system in the pathological processes underlying the
development of atherosclerosis and in particular in its ischemic
complications (Sherer and Shoenfeld, 2006). Acute ischemic brain
damage is also exacerbated by systemic inflammation. In an
experimental model of cerebral ischemia, systemic inflammation
caused sustained disruption of the tight junction protein, claudin-
5, and also exacerbated disruption of the basal lamina collagen-
IV, and these alterations were associated with an increase in
neutrophil-derived MMP-9 (McColl et al., 2008). In the same line,
systemic inflammation in IL-10 deficient mice, spontaneously
developing colitis when exposed to environmental pathogens,
increased mortality after stroke (Pérez-de Puig et al., 2013). Using
a murine model of chronic infection leading to a chronic Th1-
polarized immune response, Dénes et al. (2010) found upregula-
tion of proinflammatory mediators in the brain and peripheral
tissues, as well as an altered Treg response, accelerated platelet
aggregation in brain capillaries, increased microvascular injury
and MMP activation after experimental ischemia, and a 60%
increase in brain damage.
Infections are the most common complication in stroke
patients (Kumar et al., 2010; Westendorp et al., 2011). The most
frequent infections are respiratory infections and urinary tract
infections and the main clinical predictor of infection is the sever-
ity of the neurological deficit. Experimental and clinical studies
showed that stroke induces a transient immunodepression that
increases the susceptibility to systemic infections in the first days
after cerebral ischemia. This was first described in a murine model
of cerebral ischemia (Prass et al., 2003) where overactivation of
the adrenergic system caused apoptotic loss of lymphocytes and a
shift from Th1 to Th2 cytokine production. Atrophy of primary
and secondary lymphoid organs and increased numbers of Treg
cells were also features of the systemic immune changes induced
by cerebral ischemia (Prass et al., 2003; Offner et al., 2006). In
stroke patients, the best established features of stroke-induced
immunodepression are increased levels of stress hormones and
anti-inflammatory cytokines like IL-10 (Haeusler et al., 2008;
Klehmet et al., 2009; Urra et al., 2009a), decreased numbers
of circulating lymphocytes (Haeusler et al., 2008; Vogelgesang
et al., 2008; Urra et al., 2009b), and monocyte deactivation with
reduced expression of HLA-DR and reduced capacity to produce
inflammatory cytokines (Haeusler et al., 2008; Urra et al., 2009a).
Infection triggers inflammation, facilitates the maturation of
APCs into potent immunostimulatory cells (Banchereau et al.,
2000), and is involved in the development of autoimmune dis-
eases (Getts et al., 2013; Berer and Krishnamoorthy, 2014). Post-
stroke infections complicate the clinical course of the patients
(Ulm et al., 2012) and could be a source of inflammation favoring
autoimmunity. Systemic inflammation and infection in stroke
could set an environment in the periphery favorable to promote
the development of effector T cells against brain antigens by pro-
viding sufficient cytokines and co-stimulatory molecules (Becker,
2012). However, most features of the stroke-induced systemic
immune changes modulate antigen presentation and its con-
sequences, presumably favoring tolerogenic immune responses.
Therefore, in the absence of infection, immunodepression would
be expected to favor tolerance. Catecholamines can inhibit the
antigen-presenting capability via β2-adrenoceptors and this effect
is at least partly due to impaired CD8+ cell priming by cross-
presenting DC (Seiffert et al., 2002; Maestroni and Mazzola, 2003;
Hervé et al., 2013). Corticosteroids inhibit the production of
inflammatory cytokines in APCs and induce the development of
tolerogenic APCs (DeKruyff et al., 1998; de Jong et al., 1999), and
glucocorticoid-stimulated monocytes reduce the release of IFN-γ
and IL-17 in lymphocytes favoring the generation of Treg (Varga
et al., 2014). Interleukin-10 also inhibits autoimmune reactions
acting on several immune cells including APCs. Interleukin-10
treated DCs induce anergic T cells that are able to suppress
activation and function of T cells in an antigen-specific manner
(Steinbrink et al., 2002). In addition, other alterations in the
numbers and phenotype of circulating leukocytes, such as lym-
phocytopenia and reduced HLA-DR expression in monocytes,
could further impair the activation of specific T cell responses
against brain antigens. For all these reasons, while predisposing
patients to systemic infections, immunodepression after stroke
could limit detrimental autoimmune responses in the brain. The
effect of infection in stroke has been studied in experimen-
tal models of brain ischemia. Induction of ischemia in mice
intranasally infected with the human influenza A (H1N1) virus
increased the number of neutrophils expressing the MMP-9 in
the ischemic brain, exacerbated BBB breakdown, and increased
the rate of intracerebral hemorrhages after tissue plasminogen
activator treatment (Muhammad et al., 2011). Systemic inflam-
mation at the time of experimental stroke has been used exper-
imentally to mimic the clinical situation of infection to increase
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the likelihood of developing a detrimental autoimmune response
to brain antigens (Becker et al., 2011) by favoring Th1 responses
to MBP (Becker et al., 2005; Zierath et al., 2010). However,
induction of systemic inflammation or infection in experimental
animals at the time of cerebral ischemia would possibly mimic
better the clinical scenario of infections precipitating a stroke
rather than the infections occurring as a complication of stroke,
since the latter are usually related to the severity of the lesion
and the degree of stroke-induced immunodepression (Chamorro
et al., 2007; Dirnagl et al., 2007). Becker et al. (2011) reported
that patients who developed an infection after stroke, especially
pneumonia, were more likely to show a Th1 response to MBP and
GFAP 90 days after stroke. This is very relevant because stronger
Th1 responses to MBP were seen associated to poor functional
outcome. However, stroke associated infections are especially
frequent in patients with severe strokes (Hug et al., 2009; Urra and
Chamorro, 2010) and the development of autoimmune responses
could be strongly influenced by the severity of the brain lesion.
It is also very likely that the timing of the infections is a key
factor in modulating the immune response (Emsley and Hopkins,
2008). Infections before stroke can be a source of inflammation
and thrombosis, and can precipitate stroke onset (Elkind et al.,
2011). A small clinical study showed that patients with previous
infection had greater deficits and increased platelet activation and
platelet-leukocyte aggregation compared with patients without
infection (Zeller et al., 2005). Thus the presence of previous infec-
tions, possibly including subclinical infections, could facilitate the
occurrence of stroke and impair functional recovery.
PHARMACOLOGIC REGULATION OF AUTOREACTIVE T CELLS
AFTER STROKE
Reduction of infarct volume after transient ischemia was achieved
by immune regulation of myelin-reactive inflammatory T cells
using recombinant T cell receptor ligands (RTL), i.e., partial MHC
class II molecules covalently bound to myelin peptides acting
as partial agonists that deviate autoreactive T cells to become
non-pathogenic (Subramanian et al., 2009; Dziennis et al., 2011),
again supporting a negative effect of antigen-specific responses in
the lesion caused by stroke. Co-inhibitory molecules, like PD-1,
regulate the induction and maintenance of peripheral tolerance
(Ceeraz et al., 2013). Accordingly, PD-1-deficient mice showed
higher inflammatory responses, infarct volume and neurologi-
cal deficits after brain ischemia (Ren et al., 2011b). However,
mice deficient in PD-1 ligands (PD-L) were protected against
ischemic brain damage (Bodhankar et al., 2013b), while it has
been reported that PD-1 is necessary for Treg-induced protective
effects (Li et al., 2014). Therefore, the role of this pathway in the
outcome of brain ischemia seems to be quite complex and is not
yet fully characterized.
Regulation of the migration of lymphocyte subsets into the
CNS can also control autoimmunity. The egress of lympho-
cytes from lymph nodes requires lymphocytic S1P1 receptors
(Matloubian et al., 2004). The main protective mechanism of
fingolimod in multiple sclerosis seems to be mediated by inter-
nalization of S1P1 that therefore reduces the responsiveness of
T cells to the egress signal S1P and favors CCR7-mediated lym-
phocyte retention in lymph nodes (Pham et al., 2008). Several
experimental studies reported protection after treatment with
fingolimod in brain ischemia (Hasegawa et al., 2010; Wei et al.,
2011; Kraft et al., 2013), and intracerebral hemorrhage (Rolland
et al., 2011), but the mechanisms underlying this protection are
not fully understood. While lymphocytopenia could be involved
in the effects of fingolimod, one study found that this drug
was not protective in experimental cerebral ischemia in spite of
reducing lymphocyte influx (Liesz et al., 2011). Other effects
of this drug, including BBB protection, decreased microvascu-
lar thrombosis (Kraft et al., 2013), and reduced hemorrhagic
transformation in thromboembolic stroke (Campos et al., 2013)
could account, at least in part, for the reported beneficial effects.
Whether fingolimod affects autoimmune responses and autore-
active T cell migration after brain ischemia has not been reported
and it is unknown whether fingolimod-induced lymphocytopenia
might further increase the risk of infection. Interestingly, the
drug appears to be safe for the treatment of intracerebral hem-
orrhage in humans (Fu et al., 2014). In any case, experimental
interventions on the immune system in stroke models should pay
particular attention to immunodepression and infection as pos-
sible causes of neurological impairment and mortality. However,
studies identifying post-stroke infection in experimental animals
and its possible neurological consequences are difficult and still
infrequent (Braun et al., 2007; Engel and Meisel, 2010; Hetze et al.,
2013).
Besides systemic infections, factors such as severe arterioscle-
rosis or other systemic autoimmune diseases are also likely to
promote a proinflammatory environment favoring autoimmunity
in ischemic stroke. As vascular risk factors and atherosclerosis
are common in stroke patients, clinical and experimental studies
assessing this possibility and also the potential of commonly
used drugs, such as statins, to modulate the immune reactions
to stroke would be relevant. Several beneficial effects of statins
may be due to immunomodulatory effects, including impaired
maturation of DCs with reduced expression of molecules like
MHC class II preventing antigen presentation to T cells (Kwak
et al., 2000; Yilmaz et al., 2004) and inducing tolerogenic DCs that
increase the numbers of Treg cells (Li et al., 2013c). Vaccination
is also an attractive approach to induce protective immunity
avoiding the progression of atherosclerosis. In experiments in
animals, atherosclerosis was reduced by vaccination with oxidized
LDL, bacteria containing certain modified phospholipids, or heat-
shock protein 65 (Palinski et al., 1995; Maron et al., 2002; Binder
et al., 2003).
FUTURE DIRECTIONS
In this review we described the current evidence suggesting
the possibility that stroke can trigger antigen-specific responses.
These include the finding of T-cells autoreactive to brain antigens
in stroke patients, the presence of brain antigens and autoanti-
bodies in CSF and serum, and APCs carrying brain antigens in
the regional lymphoid tissue. Further support to this notion is
provided by the beneficial effects of inducing immune tolerance
in experimental animal models of stroke. Brain antigens are
released after stroke in the presence of inflammatory mediators
and danger signals. Soluble molecules can reach the periphery
across the leaky BBB or across natural pathways normally allowing
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fluid efflux, i.e., the drainage of interstitial fluid to the CSF
and from there to the blood, and the drainage of CSF through
the nasal lymphatics to the cervical lymph nodes. Furthermore,
antigens can be internalized locally in the brain by APCs, but
whether these cells can migrate to the draining lymph nodes for
efficient antigen presentation is currently unknown and deserves
further investigation. Since these routes could trigger different
immune responses, it is relevant to elucidate their contribution to
brain antigen transfer to the lymph nodes. Mechanisms ensuring
tolerance to self are tightly regulated. Peripheral tolerance relies
on factors including the features of APCs and their interaction
with lymphocytes, the cytokine environment, and the presence
of danger signals and regulatory or suppressor cells. Although a
number of studies have shown specific changes in these factors
after stroke, we still lack a complete picture of how these changes
are integrated in the organism over time. Furthermore, stroke
co-morbidities are often associated with changes in the immune
system that could play a crucial role in directing specific immune
responses to stroke. Stroke does not consistently trigger autoim-
munity, but several lines of evidence support that infection and
inflammation could break immune tolerance controls and favor
autoreactive responses to brain antigens after stroke. Infection is
a frequent complication of stroke that is attributable to stroke-
induced immunodepression, characterized by acute lymphopenia
and monocyte deactivation. Immunodepression sets a humoral
and cellular situation favorable to prevent autoreactivity, but
leaves the subjects at risk of infection. In the event of infection,
the risk of autoreactivity increases, suggesting a fine balance
between the factors regulating tolerance and autoimmunity. Fur-
ther understanding of these regulatory mechanisms is necessary
to elucidate whether antigen-specific reactions could threaten the
outcome of stroke patients. Some patients show partial recovery
of function and respond to rehabilitation over months after
stroke onset. However, certain stroke patients develop compli-
cations, as for instance cognitive decline or epilepsy, and it
is often difficult to predict such effects. Whether any autoim-
mune reaction can underlie stroke complications deserves fur-
ther investigation aiming to prevent or attenuate such adverse
events.
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